Published in Cancer Cell on June 15, 2010
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem (2012) 3.61
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
RNA polymerase II elongation control. Annu Rev Biochem (2012) 3.09
Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol (2011) 2.56
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Chromatin signaling to kinetochores: transregulation of Dam1 methylation by histone H2B ubiquitination. Cell (2011) 2.30
The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell (2010) 2.06
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Transcriptional activators enhance polyadenylation of mRNA precursors. Mol Cell (2011) 2.01
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood (2011) 1.74
Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A (2011) 1.56
Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell (2014) 1.52
PAF Complex Plays Novel Subunit-Specific Roles in Alternative Cleavage and Polyadenylation. PLoS Genet (2016) 1.45
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain. Nat Commun (2011) 1.37
The many roles of the conserved eukaryotic Paf1 complex in regulating transcription, histone modifications, and disease states. Biochim Biophys Acta (2012) 1.32
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem Soc Trans (2013) 1.30
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep (2013) 1.22
SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci (2013) 1.22
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure (2012) 1.18
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.17
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer (2015) 1.12
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood (2012) 1.01
ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood (2011) 0.99
The X-linked intellectual disability protein PHF6 associates with the PAF1 complex and regulates neuronal migration in the mammalian brain. Neuron (2013) 0.96
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene (2012) 0.95
Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J Cell Sci (2011) 0.92
The Roles of the Paf1 Complex and Associated Histone Modifications in Regulating Gene Expression. Genet Res Int (2011) 0.90
Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism. Front Cell Dev Biol (2015) 0.90
PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget (2010) 0.89
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem (2014) 0.89
Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia (2015) 0.89
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. Cell Rep (2014) 0.89
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun (2014) 0.88
Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood (2015) 0.88
Linker Histone H1.2 cooperates with Cul4A and PAF1 to drive H4K31 ubiquitylation-mediated transactivation. Cell Rep (2013) 0.87
MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep (2013) 0.86
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer. PLoS One (2011) 0.86
Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol (2014) 0.85
Menin as a hub controlling mixed lineage leukemia. Bioessays (2012) 0.85
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
The Paf1 complex represses ARG1 transcription in Saccharomyces cerevisiae by promoting histone modifications. Eukaryot Cell (2011) 0.84
Leukaemia: MLL makes friends and influences. Nat Rev Cancer (2010) 0.83
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) (2012) 0.83
Structural insights into Paf1 complex assembly and histone binding. Nucleic Acids Res (2013) 0.82
Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem (2013) 0.81
MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood (2015) 0.81
p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol (2013) 0.80
The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. Blood (2014) 0.80
The upstreams and downstreams of H3K79 methylation by DOT1L. Chromosoma (2016) 0.79
MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood (2013) 0.79
Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood (2014) 0.79
A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. Leukemia (2014) 0.79
Transcriptional activators enhance polyadenylation of mRNA precursors. RNA Biol (2011) 0.79
Chromatin modification by the RNA Polymerase II elongation complex. Transcription (2015) 0.78
Ctr9, a Key Component of the Paf1 Complex, Affects Proliferation and Terminal Differentiation in the Developing Drosophila Nervous System. G3 (Bethesda) (2016) 0.78
WDR5 high expression and its effect on tumorigenesis in leukemia. Oncotarget (2016) 0.77
p53 downregulates the Fanconi anaemia DNA repair pathway. Nat Commun (2016) 0.77
DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun (2016) 0.77
Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nat Cell Biol (2017) 0.76
Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways. Ann Lab Med (2016) 0.76
The molecular mechanics of mixed lineage leukemia. Oncogene (2016) 0.76
PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity. Mol Cell (2016) 0.75
Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem (2016) 0.75
MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discov (2016) 0.75
Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol (2014) 0.75
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Cell Rep (2017) 0.75
The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. Leukemia (2016) 0.75
Systematic identification of Ctr9 regulome in ERα-positive breast cancer. BMC Genomics (2016) 0.75
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther (2000) 12.54
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature (2002) 7.54
The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell (2003) 7.47
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A (1999) 5.33
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell (2006) 5.14
Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. J Biol Chem (2002) 4.75
Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell (2007) 4.49
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Exchange of RNA polymerase II initiation and elongation factors during gene expression in vivo. Mol Cell (2002) 4.35
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell (2005) 4.04
Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J (1997) 4.03
Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev (2003) 4.00
RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell (2009) 3.82
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. Cell Stem Cell (2009) 3.55
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J Biol Chem (2003) 3.08
MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med (2004) 2.97
Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J (2006) 2.89
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell (2007) 2.82
The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev (2005) 2.70
The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol (2005) 2.58
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet (1997) 2.45
Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. Mol Cell Biol (2008) 2.34
Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell (2007) 2.23
Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) (2006) 2.01
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol (2004) 1.94
Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood (2003) 1.93
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene (2005) 1.56
Regulation of Hox gene activity by transcriptional elongation in Drosophila. Curr Biol (2009) 1.55
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
A novel collection of accessory factors associated with yeast RNA polymerase II. Protein Expr Purif (1996) 1.49
Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet (1995) 1.32
Parafibromin--functional insights. J Intern Med (2009) 1.15
Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene (2008) 1.15
Chromosomal translocations involving the MLL gene: molecular mechanisms. DNA Repair (Amst) (2006) 1.11
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene (2006) 1.11
Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene (2007) 0.92
Isolation and characterization of a complementary DNA (PD-1) differentially expressed by human pancreatic ductal cell tumors. Cell Growth Differ (1991) 0.82
The molecular classification of multiple myeloma. Blood (2006) 8.77
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
Vimentin is secreted by activated macrophages. Nat Cell Biol (2003) 2.63
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle (2008) 1.90
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood (2009) 1.90
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med (2014) 1.81
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell (2003) 1.79
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A (2006) 1.67
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A (2011) 1.65
Anaplastic Large Cell Lymphoma. Am J Clin Pathol (2007) 1.64
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene (2005) 1.64
Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood (2011) 1.63
Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest (2005) 1.63
An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS One (2010) 1.52
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47
Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J Virol (2005) 1.46
Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.42
The advent of targeted therapeutics and implications for pathologists. Am J Clin Pathol (2002) 1.38
A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One (2013) 1.37
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell (2009) 1.36
Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities. Infect Immun (2003) 1.36
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol (2010) 1.35
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol (2009) 1.33
Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood (2002) 1.33
Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop (2009) 1.31
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood (2003) 1.28
The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol (2006) 1.27
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol (2007) 1.26
A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection. Infect Immun (2005) 1.26
Abacus: a computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis. Proteomics (2011) 1.24
Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene (2004) 1.24
The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood (2008) 1.18
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem (2010) 1.16
Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286). J Phys Chem B (2012) 1.14
HOX proteins and leukemia. Int J Clin Exp Pathol (2008) 1.14
Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol Biol (2009) 1.13
Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J Biol Chem (2010) 1.12
Identification of a Francisella tularensis LVS outer membrane protein that confers adherence to A549 human lung cells. FEMS Microbiol Lett (2006) 1.09
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood (2004) 1.09
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene (2005) 1.04
A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun (2006) 1.03
Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. J Hematop (2009) 1.03
Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol (2002) 1.03
Regulation of the copper chaperone CCS by XIAP-mediated ubiquitination. Mol Cell Biol (2010) 1.03
The ubiquitin-conjugating enzyme (E2) Ube2w ubiquitinates the N terminus of substrates. J Biol Chem (2013) 1.03
High-resolution melting analysis for detection of internal tandem duplications. J Mol Diagn (2004) 1.01
Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics (2011) 0.99
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.99
MLL core components give the green light to histone methylation. ACS Chem Biol (2006) 0.99
ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood (2011) 0.99
Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteomics (2005) 0.98
Multivalent recombinant protein vaccine against coccidioidomycosis. Infect Immun (2006) 0.98
The molecular pathology of primary immunodeficiencies. J Mol Diagn (2004) 0.98
Ouabain decreases sarco(endo)plasmic reticulum calcium ATPase activity in rat hearts by a process involving protein oxidation. Am J Physiol Heart Circ Physiol (2006) 0.96
DEK binding to class II MHC Y-box sequences is gene- and allele-specific. Arthritis Res Ther (2003) 0.94
Sequence alignment by cross-correlation. J Biomol Tech (2005) 0.93
Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics (2007) 0.92
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood (2009) 0.91
Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells. Steroids (2006) 0.91
High-throughput analysis of protein/peptide complexes by immunoprecipitation and automated LC-MS/MS. J Biomol Tech (2003) 0.91
Analysis of phosphatase and tensin homolog tumor suppressor interacting proteins by in vitro and in silico proteomics. Proteomics (2005) 0.91
Conjugated polyelectrolyte-antibody hybrid materials for highly fluorescent live cell-imaging. Adv Mater (2012) 0.90
Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med (2010) 0.90
Proteomics in pathology research. Lab Invest (2004) 0.90
PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget (2010) 0.89
Involvement of reactive oxygen species in a feed-forward mechanism of Na/K-ATPase-mediated signaling transduction. J Biol Chem (2013) 0.89